JP2006501167A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006501167A5 JP2006501167A5 JP2004510828A JP2004510828A JP2006501167A5 JP 2006501167 A5 JP2006501167 A5 JP 2006501167A5 JP 2004510828 A JP2004510828 A JP 2004510828A JP 2004510828 A JP2004510828 A JP 2004510828A JP 2006501167 A5 JP2006501167 A5 JP 2006501167A5
- Authority
- JP
- Japan
- Prior art keywords
- bone
- receptor
- cells
- opgl
- osteoclast
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000014128 RANK Ligand Human genes 0.000 description 16
- 108010025832 RANK Ligand Proteins 0.000 description 16
- 108020003175 receptors Proteins 0.000 description 14
- 102000005962 receptors Human genes 0.000 description 14
- 210000002997 osteoclast Anatomy 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 8
- 102100021396 Cell surface glycoprotein CD200 receptor 1 Human genes 0.000 description 7
- 101000969553 Homo sapiens Cell surface glycoprotein CD200 receptor 1 Proteins 0.000 description 7
- 210000000963 osteoblast Anatomy 0.000 description 7
- 102100032236 Tumor necrosis factor receptor superfamily member 11B Human genes 0.000 description 6
- 230000014461 bone development Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 210000002449 bone cell Anatomy 0.000 description 4
- 230000004097 bone metabolism Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 2
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 108010035042 Osteoprotegerin Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- XYZZKVRWGOWVGO-UHFFFAOYSA-N Glycerol-phosphate Chemical compound OP(O)(O)=O.OCC(O)CO XYZZKVRWGOWVGO-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 description 1
- 101000605020 Homo sapiens Large neutral amino acids transporter small subunit 1 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229940123425 Osteoblast inhibitor Drugs 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 101150086605 Runx2 gene Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002745 epiphysis Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000024121 nodulation Effects 0.000 description 1
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000004072 osteoblast differentiation Effects 0.000 description 1
- 208000002865 osteopetrosis Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000005487 simulated microgravity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38656402P | 2002-06-07 | 2002-06-07 | |
| US60/386,564 | 2002-06-07 | ||
| PCT/CA2003/000823 WO2003103709A2 (en) | 2002-06-07 | 2003-06-06 | Modulation of bone development |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010006754A Division JP2010155843A (ja) | 2002-06-07 | 2010-01-15 | 骨発生の調節方法 |
| JP2010175910A Division JP2010285448A (ja) | 2002-06-07 | 2010-08-05 | 骨発生の調節方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006501167A JP2006501167A (ja) | 2006-01-12 |
| JP2006501167A5 true JP2006501167A5 (https=) | 2010-10-28 |
| JP4763282B2 JP4763282B2 (ja) | 2011-08-31 |
Family
ID=29736181
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004510828A Expired - Fee Related JP4763282B2 (ja) | 2002-06-07 | 2003-06-06 | 骨発生の調節方法 |
| JP2010006754A Pending JP2010155843A (ja) | 2002-06-07 | 2010-01-15 | 骨発生の調節方法 |
| JP2010175910A Withdrawn JP2010285448A (ja) | 2002-06-07 | 2010-08-05 | 骨発生の調節方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010006754A Pending JP2010155843A (ja) | 2002-06-07 | 2010-01-15 | 骨発生の調節方法 |
| JP2010175910A Withdrawn JP2010285448A (ja) | 2002-06-07 | 2010-08-05 | 骨発生の調節方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20050287603A1 (https=) |
| EP (1) | EP1532176A2 (https=) |
| JP (3) | JP4763282B2 (https=) |
| AU (2) | AU2003233721B2 (https=) |
| CA (1) | CA2487428A1 (https=) |
| WO (1) | WO2003103709A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2462883A1 (en) * | 2001-10-12 | 2003-04-17 | Schering Corporation | Use of bispecific antibodies to regulate immune responses |
| MXPA05006978A (es) * | 2002-12-27 | 2005-08-16 | Schering Corp | Metodos para inducir y mantener la tolerancia inmune. |
| AU2008206502A1 (en) * | 2007-01-11 | 2008-07-24 | Boehringer Ingelheim International Gmbh | CD200 and its receptor, CD200R, modulate bone mass via the differentiation of osteoclasts |
| US8647871B2 (en) | 2007-03-30 | 2014-02-11 | Escape Therapeutics, Inc. | Endogenous expression of HLA-G and/or HLA-E by mesenchymal cells |
| WO2014113704A2 (en) | 2013-01-18 | 2014-07-24 | Escape Therapeutics, Inc. | Enhanced differentiation of mesenchymal stem cells |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5641747A (en) * | 1994-07-25 | 1997-06-24 | Temple University-Of The Commonwealth System Of Higher Education | Treatment of osteopetrotic diseases |
| US20020192215A1 (en) * | 1999-04-13 | 2002-12-19 | Schering Corporation, A New Jersey Corporation | Novel uses of mammalian OX2 protein and related reagents |
| DE60034871T2 (de) * | 1999-09-03 | 2008-01-17 | Amgen Inc., Thousand Oaks | Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust |
| KR20040028601A (ko) * | 2000-09-05 | 2004-04-03 | 더 락커펠러 유니버시티 | 파골세포-관련 수용체 |
| DK1482973T3 (da) * | 2002-03-15 | 2009-12-07 | Schering Corp | Fremgangsmåde til modulering af CD200-receptorer |
-
2003
- 2003-06-06 WO PCT/CA2003/000823 patent/WO2003103709A2/en not_active Ceased
- 2003-06-06 AU AU2003233721A patent/AU2003233721B2/en not_active Ceased
- 2003-06-06 US US10/515,332 patent/US20050287603A1/en not_active Abandoned
- 2003-06-06 JP JP2004510828A patent/JP4763282B2/ja not_active Expired - Fee Related
- 2003-06-06 CA CA002487428A patent/CA2487428A1/en not_active Abandoned
- 2003-06-06 EP EP03727091A patent/EP1532176A2/en not_active Withdrawn
-
2009
- 2009-02-27 US US12/394,621 patent/US20090214573A1/en not_active Abandoned
- 2009-09-23 AU AU2009217461A patent/AU2009217461A1/en not_active Abandoned
-
2010
- 2010-01-15 JP JP2010006754A patent/JP2010155843A/ja active Pending
- 2010-08-05 JP JP2010175910A patent/JP2010285448A/ja not_active Withdrawn
-
2011
- 2011-04-11 US US13/084,009 patent/US20110189201A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Onyia et al. | In vivo demonstration that human parathyroid hormone 1–38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene | |
| Daponte et al. | Current perspectives on the multiple roles of osteoclasts: mechanisms of osteoclast–osteoblast communication and potential clinical implications | |
| Hiraga et al. | Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases | |
| Hofbauer et al. | The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption | |
| Alexaki et al. | Adipocytes as immune cells: differential expression of TWEAK, BAFF, and APRIL and their receptors (Fn14, BAFF-R, TACI, and BCMA) at different stages of normal and pathological adipose tissue development | |
| Kon et al. | Expression of osteoprotegerin, receptor activator of NF‐κB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing | |
| Gerstenfeld et al. | Impaired intramembranous bone formation during bone repair in the absence of tumor necrosis factor-alpha signaling | |
| Cornish et al. | Interleukin-18 is a novel mitogen of osteogenic and chondrogenic cells | |
| JPH09504030A (ja) | Ｃｎｔｆ族アンタゴニスト | |
| JP4660471B2 (ja) | ＴＧＦβ結合タンパク質のリガンドおよびその使用 | |
| JPH05509312A (ja) | 組織由来の腫瘍増殖インヒビター，その調製方法及び使用 | |
| JP2003534022A (ja) | Ｒａｎｋリガンド介在障害の治療に有用な抗−ｒａｎｋリガンドモノクローナル抗体 | |
| US6998123B1 (en) | Osteoporosis treatment with anti-IL-11 antibody | |
| JP2001512667A (ja) | ヒトオーファンレセプターｎｔｒ−１ | |
| Liu et al. | Estrogen inhibition of PTH-stimulated osteoclast formation and attachment in vitro: involvement of both PKA and PKC | |
| Nakao et al. | Collaborative action of M-CSF and CTGF/CCN2 in articular chondrocytes: possible regenerative roles in articular cartilage metabolism | |
| US20110189201A1 (en) | Modulation of bone development | |
| JP2006501167A5 (https=) | ||
| JP2002501902A (ja) | リンホトキシン（ｌｔ）経路のインヒビターを使用する濾胞性リンパ腫の処置 | |
| Zeng et al. | IgG immunocomplexes drive the differentiation of a novel subset of osteoclasts independent of RANKL and inflammatory cytokines | |
| Nguyen et al. | Ciona intestinalis calcitonin-like peptide promotes osteoblast differentiation and mineralization through MAPK pathway in MC3T3-E1 cells | |
| JP2000510112A (ja) | ＴＧＦ―β拮抗物質としてのプロラクチンの使用方法 | |
| US6248326B1 (en) | Regulation of osteoclast formation by inhibition of osteoblastic stem cell factor | |
| CA2538229A1 (en) | Treatment of rheumatoid arthritis with cd99 antagonists | |
| JP2002509693A (ja) | カドヘリン由来成長因子及びその使用 |